• 作者：Gemma Aragonè ; s ; Raimon Ferré ; Nú ; ria Plana ; Jordi Merino ; Josefa Girona ; Lluí ; s Masana ; ^{luis.masana@urv.cat}
• 关键词：FABP4 ; Funci&oacute ; n endotelial ; Diabetes tipo 2 ; Hiperemia reactiva ; Riesgo cardiovascular
• 刊名：Cl铆nica e Investigaci贸n en Arteriosclerosis
• 出版年：2011
• 期刊代码：pca88_02149168
• 类别：med
• 出版时间：September-October 2011
• 卷：23
• 期：5
• 页码：211-218
• 文件大小：160 K

Objective

Adipocyte fatty acid binding protein (FABP4) plasma levels are higher in type 2 diabetes (T2D), obesity and metabolic syndrome. Endothelial dysfunction is a common feature in the development of vascular diseases associated with metabolic disturbances. We have investigated the relationship between circulating FABP4 levels and endothelial function in patients at cardiovascular risk.

Methods

Two hundred and fifty-seven patients (mean age, 57.29 卤 10.66 years) at increased cardiovascular risk (CVR). Fasting plasma FABP4 levels were measured. Endothelial function was assessed as reactive hyperemia (IHR) by peripheral artery tonometry (PAT), carotid intima-media thickness and ankel-brachial index. Antropometry and endothelial, inflammation and oxidation biomarkers were measured.

Results

FABP4 was negatively associated with endothelial function, as measured by the IHR (r=-.226, <em>Pem>=.027) in T2D subjects. There was a significant inverse association of the IHR across FABP4 tertiles (<em>Pem>=.023). In a stepwise multivariable linear regression model, FABP4 was a predictor of IHR in T2D patients (<em>Pem><.05). FABP4 levels were higher in T2D patients. We also observed a significant positive correlation between FABP4 and BMI (r=.211; <em>Pem>=.03) and Ab ox-LDL (r=.251; <em>Pem>=.01). The correlation between FABP4 and IHR was maintained after adjusting for these confounding variables. There were not significance differences in GIM and ABI among patients.

Conclusion

High circulating levels of FABP4 are associated with worse endothelial function, as measured by IHR in T2D patients. We suggest a direct effect of plasma FABP4 on the vascular endothelium in T2D patients.